MedImmune LLC
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-12-08
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 1200
- Registration Number
- NCT00192166
- Locations
- 🇸🇬
Respiratory Medicine Service, Singapore, Singapore
Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-09-22
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 3022
- Registration Number
- NCT00192218
- Locations
- 🇺🇸
Division of General Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, United States
🇺🇸Division of Allergy and Infectious Diseases, University of Washington School of Medicine, Seattle, Washington, United States
Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-07-28
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 217
- Registration Number
- NCT00192478
- Locations
- 🇦🇷
Hospital General de Niños "Ricardo Gutierrez", Buenos Aires, Argentina
🇨🇱Hospital Clinico Pontificia Universidad Catolica de Chile, Santiago, Chile
🇦🇷Hospital Interzonal General de Agudos "Dr. Diego Paroissien, Buenos Aires, Argentina
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 120
- Registration Number
- NCT00192231
- Locations
- 🇦🇺
Austin & Repatriation Medical Centre, Heidelburg, Victoria, Australia
Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00192387
- Locations
- 🇺🇸
Monroe Clinic, Monroe, Wisconsin, United States
Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 300
- Registration Number
- NCT00192127
- Locations
- 🇺🇸
SFBC International, Inc, Miami, Florida, United States
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 240
- Registration Number
- NCT00192153
- Locations
- 🇺🇸
West Coast Medical Associates, New Port Richey, Florida, United States
🇺🇸University of VA Health Sciences Center, Charlottesville, Virginia, United States
Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2014-03-06
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00192296
- Locations
- 🇺🇸
MDS Pharma Services, New Orleans, Louisiana, United States
Long-Term Follow-Up Study of Psoriasis Patients
- Conditions
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2008-09-22
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 200
- Registration Number
- NCT00131066
- Locations
- 🇺🇸
Cherry Creek Dermatology, Denver, Colorado, United States
🇺🇸Future Care Studies, Springfield, Massachusetts, United States
🇧🇪Universitaur Ziekenhuis Gent, Gent, Belgium
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
- Conditions
- Interventions
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 6635
- Registration Number
- NCT00129766
- Locations
- 🇺🇸
Kaiser Permanente Los Angeles, Los Angeles, California, United States
🇺🇸Emory University School Of Medicine, Atlanta, Georgia, United States
🇺🇸Lehigh Valley Hospital, Allentown, Pennsylvania, United States